Cargando…
Pyruvate is a prospective alkalizer to correct hypoxic lactic acidosis
Type A lactic acidosis resulted from hypoxic mitochondrial dysfunction is an independent predictor of mortality for critically ill patients. However, current therapeutic agents are still in shortage and can even be harmful. This paper reviewed data regarding lactic acidosis treatment and recommended...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918562/ https://www.ncbi.nlm.nih.gov/pubmed/29695298 http://dx.doi.org/10.1186/s40779-018-0160-y |
_version_ | 1783317444318724096 |
---|---|
author | Wang, Ying Huang, Ya Yang, Jing Zhou, Fang-Qiang Zhao, Lian Zhou, Hong |
author_facet | Wang, Ying Huang, Ya Yang, Jing Zhou, Fang-Qiang Zhao, Lian Zhou, Hong |
author_sort | Wang, Ying |
collection | PubMed |
description | Type A lactic acidosis resulted from hypoxic mitochondrial dysfunction is an independent predictor of mortality for critically ill patients. However, current therapeutic agents are still in shortage and can even be harmful. This paper reviewed data regarding lactic acidosis treatment and recommended that pyruvate might be a potential alkalizer to correct type A lactic acidosis in future clinical practice. Pyruvate is a key energy metabolic substrate and a pyruvate dehydrogenase (PDH) activator with several unique beneficial biological properties, including anti-oxidant and anti-inflammatory effects and the ability to activate the hypoxia-inducible factor-1 (HIF-1α) - erythropoietin (EPO) signal pathway. Pyruvate preserves glucose metabolism and cellular energetics better than bicarbonate, lactate, acetate and malate in the efficient correction of hypoxic lactic acidosis and shows few side effects. Therefore, application of pyruvate may be promising and safe as a novel therapeutic strategy in hypoxic lactic acidosis correction accompanied with multi-organ protection in critical care patients. |
format | Online Article Text |
id | pubmed-5918562 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-59185622018-05-02 Pyruvate is a prospective alkalizer to correct hypoxic lactic acidosis Wang, Ying Huang, Ya Yang, Jing Zhou, Fang-Qiang Zhao, Lian Zhou, Hong Mil Med Res Review Type A lactic acidosis resulted from hypoxic mitochondrial dysfunction is an independent predictor of mortality for critically ill patients. However, current therapeutic agents are still in shortage and can even be harmful. This paper reviewed data regarding lactic acidosis treatment and recommended that pyruvate might be a potential alkalizer to correct type A lactic acidosis in future clinical practice. Pyruvate is a key energy metabolic substrate and a pyruvate dehydrogenase (PDH) activator with several unique beneficial biological properties, including anti-oxidant and anti-inflammatory effects and the ability to activate the hypoxia-inducible factor-1 (HIF-1α) - erythropoietin (EPO) signal pathway. Pyruvate preserves glucose metabolism and cellular energetics better than bicarbonate, lactate, acetate and malate in the efficient correction of hypoxic lactic acidosis and shows few side effects. Therefore, application of pyruvate may be promising and safe as a novel therapeutic strategy in hypoxic lactic acidosis correction accompanied with multi-organ protection in critical care patients. BioMed Central 2018-04-26 /pmc/articles/PMC5918562/ /pubmed/29695298 http://dx.doi.org/10.1186/s40779-018-0160-y Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Wang, Ying Huang, Ya Yang, Jing Zhou, Fang-Qiang Zhao, Lian Zhou, Hong Pyruvate is a prospective alkalizer to correct hypoxic lactic acidosis |
title | Pyruvate is a prospective alkalizer to correct hypoxic lactic acidosis |
title_full | Pyruvate is a prospective alkalizer to correct hypoxic lactic acidosis |
title_fullStr | Pyruvate is a prospective alkalizer to correct hypoxic lactic acidosis |
title_full_unstemmed | Pyruvate is a prospective alkalizer to correct hypoxic lactic acidosis |
title_short | Pyruvate is a prospective alkalizer to correct hypoxic lactic acidosis |
title_sort | pyruvate is a prospective alkalizer to correct hypoxic lactic acidosis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918562/ https://www.ncbi.nlm.nih.gov/pubmed/29695298 http://dx.doi.org/10.1186/s40779-018-0160-y |
work_keys_str_mv | AT wangying pyruvateisaprospectivealkalizertocorrecthypoxiclacticacidosis AT huangya pyruvateisaprospectivealkalizertocorrecthypoxiclacticacidosis AT yangjing pyruvateisaprospectivealkalizertocorrecthypoxiclacticacidosis AT zhoufangqiang pyruvateisaprospectivealkalizertocorrecthypoxiclacticacidosis AT zhaolian pyruvateisaprospectivealkalizertocorrecthypoxiclacticacidosis AT zhouhong pyruvateisaprospectivealkalizertocorrecthypoxiclacticacidosis |